



## **Aurobindo Pharma receives tentative approval for Sumatriptan Succinate Tablets**

Aurobindo Pharma Limited is pleased to announce that the company has received tentative approval from the US Food & Drug Administration to manufacture and market Sumatriptan Succinate Tablets 25mg, 50mg and 100mg.

Sumatriptan Succinate Tablets are the generic equivalent of GlaxoSmithKline's Imitrex® Tablets, which are indicated for the treatment of acute migraine headaches.

Annual sales of Sumatriptan Succinate Tablets 25mg, 50mg and 100mg in the US were approximately US\$ 950 million for the twelve months ending MAT/3/2007 according to IMS Health data

This is Aurobindo's 63rd ANDA approval from the USFDA

### **About Aurobindo Pharma Limited:**

Aurobindo Pharma Limited ([www.aurobindo.com](http://www.aurobindo.com)), headquartered at Hyderabad, India, manufactures generic pharmaceuticals and active pharmaceutical ingredients. The company's manufacturing facilities are approved by several leading regulatory agencies like US FDA, UK MHRA, WHO, Health Canada, MCC South Africa. The company's robust product portfolio is spread over 6 major therapeutic/product areas encompassing Antibiotics, Anti-Retrovirals, CVS, CNS, Gastroenterologicals, and Anti-Allergics. The Company is marketing these products globally, in over 100 countries.

### **For further information, please contact:**

Investor Relations

Aurobindo Pharma Limited

Reg Off: Plot No. 2, Maitrivihar

Ameerpeth, Hyderabad

Phone: 040-66725000

Email: [ir@aurobindo.com](mailto:ir@aurobindo.com)